Safety and Efficacy Study of GRT6005 in Patients With Osteoarthritis (OA) Knee Pain
Status:
Completed
Trial end date:
2014-04-04
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of GRT6005 compared to
placebo in patients with moderate to severe chronic pain due to osteoarthritis (OA) of the
knee. This study includes a maximum 21 day Screening Period followed by a 15-week
Double-blind Treatment Period and a 4-7 day Safety Follow-up period. Patients who are
eligible for the Double-blind Treatment Period will be randomized to one of following
treatment groups: GRT6005 high-dose range (400, 600 or 800 mcg), GRT6005 low-dose range (200,
300 or 400 mcg), oxycodone controlled release (CR) dose range (10, 20, 30, 40 or 50 mg) or
placebo.